Swiss Pharmaceuticals BOLADROL 60mg 50 Caps

Description

Swiss Pharmaceuticals BOLADROL 60mg 50 Caps

Swiss Pharmaceuticals BOLADROL 60mg 50 Caps is a specialist multi-compound capsule product containing three individually declared research compounds: MK-677, LGD-4033 and GW501516.

Each original container provides 50 capsules. According to the manufacturer’s product information, one capsule contains 30 mg of MK-677, 15 mg of LGD-4033 and 15 mg of GW501516, providing a total declared specification of 60 mg per capsule. Gelatin and magnesium stearate are listed as additional ingredients.

Three-compound formula

The declared formula includes:

• MK-677 Ibutamoren – 30 mg
• LGD-4033 Ligandrol – 15 mg
• GW501516 Cardarine – 15 mg
• Total declared amount – 60 mg per capsule
• Package size – 50 capsules

Although BOLADROL is marketed as a SARM stack, the three compounds do not belong to the same pharmacological category. LGD-4033 is an investigational selective androgen receptor modulator. MK-677 is a non-peptide growth-hormone secretagogue, while GW501516 is a PPAR-delta agonist rather than a SARM.

Product presentation

Swiss Pharmaceuticals BOLADROL is supplied in a compact capsule container displaying the brand name, product designation and package specifications.

A complete catalogue listing should allow the customer to verify:

• the Swiss Pharmaceuticals branding,
• the BOLADROL product name,
• the 50-capsule package size,
• the declared amount of each compound,
• the complete ingredient panel,
• the batch and expiry details,
• the product verification code,
• the condition of the original safety seal.

The manufacturer provides an online product-code verification system. The physical label should remain the primary source for the final composition, warnings and storage information.

Responsible catalogue information

BOLADROL is frequently promoted using claims concerning muscle growth, fat reduction, strength, endurance and recovery. Such statements should not be presented as guaranteed, medically approved or clinically established benefits of the commercial product.

The product should not be described as an ordinary vitamin, conventional sports supplement or approved medical treatment. A responsible listing should focus on verifiable information such as the compound names, declared amounts, package size and original packaging.

Safety and regulatory information

MK-677, LGD-4033 and GW501516 are investigational compounds. The United States FDA has issued enforcement warnings concerning products marketed with these substances, treating them as unapproved new drugs when promoted for human performance or therapeutic purposes. The FDA has also highlighted potentially serious risks associated with products containing SARMs, including liver injury and increased cardiovascular risk.

The presence of three active compounds in one capsule should not be interpreted as evidence of safety, effectiveness or suitability for a particular person.

Information for tested athletes

The ingredients in BOLADROL fall within categories prohibited under the World Anti-Doping Agency’s 2026 Prohibited List. Athletes and other individuals subject to anti-doping controls should treat the entire formula as prohibited in sport.

This description is provided solely for product identification and catalogue-reference purposes. It does not contain medical advice, dosage instructions, cycle guidance, stacking recommendations or guarantees of physical or performance-related results.